Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Using Patent Data to Anticipate Shortage Conditions Patent intelligence is useful not only for identifying savings opportunities but also for anticipating shortage risks
GobyMeds GLP-1 Program Options: What's Available for Eligible Patients GobyMeds lists the following programs among its offerings for eligible patients: Compounded Semaglutide - a compounded GLP-1 receptor agonist program for weight management, starting at $99/month Compounded Tirzepatide - a compounded dual GIP/GLP-1 receptor agonist program, starting at $133/month NAD+ - cellular energy and metabolic support, starting at $116/month Sermorelin - peptide therapy designed to support natural growth hormone release, starting at $199/month Brand-name medications - GobyMeds lists Wegovy, Zepbound, Mounjaro, and Ozempic as available for eligible patients with limited supply Semaglutide is commonly discussed as a GLP-1 receptor agonist
2007 Sep 10;570(1-3):212-21
in: PubMed | Google Scholar Authorship note: MS and MMH contributed equally to this work
Learn what the journey looks like and how we support you in making meaningful, lasting progress
US$ 24.83
US$ 28.57
US$ 20.72
US$ 28.52
US$ 26.67
